Welcome to our dedicated page for Allakos news (Ticker: ALLK), a resource for investors and traders seeking the latest updates and insights on Allakos stock.
Allakos Inc. reports developments as a biotechnology company that has developed antibody therapeutics for allergic, inflammatory and proliferative diseases. Company news has centered on AK006, a Siglec-6 monoclonal antibody designed to inhibit mast cells, including Phase 1 safety, pharmacokinetic, pharmacodynamic and chronic spontaneous urticaria results.
Recent updates also cover the discontinuation of AK006 development, restructuring activities to reduce costs, exploration of strategic alternatives, financial results and cash-position commentary. Other recurring items include material agreements, capital-structure disclosures and governance matters tied to the company’s public-company status.
Allakos Inc. (Nasdaq: ALLK) reported significant findings from a study that indicates eosinophilic gastritis (EG) and eosinophilic duodenitis (EoD) are underdiagnosed in patients with chronic gastrointestinal symptoms. The study showed that 45% of symptomatic patients biopsied met the histologic criteria for these diseases. A total of 556 patients were screened, with 405 meeting symptom criteria for biopsy. The results suggest a potential market opportunity for lirentelimab (AK002), currently in clinical trials. A conference call is scheduled for today at 8:00 am ET.
Allakos Inc. (Nasdaq: ALLK) published Phase 2 study results of lirentelimab (AK002) in eosinophilic gastritis and duodenitis, revealing statistically significant improvements over placebo on primary and secondary endpoints. Key findings included reduced gastrointestinal tissue eosinophil counts and enhanced patient-reported symptoms. Lirentelimab has orphan drug designation for these conditions, addressing severe inflammatory diseases lacking approved treatments. The positive peer-reviewed publication in the New England Journal of Medicine bolsters the potential market impact for lirentelimab.
Allakos Inc. (Nasdaq: ALLK) is advancing its clinical studies for antolimab (AK002) targeting eosinophilic diseases. A Phase 3 study for eosinophilic gastritis and/or duodenitis is enrolling 160 patients, while a Phase 2/3 study for eosinophilic esophagitis aims to recruit 300 patients. Top-line results from both studies are anticipated in the second half of 2021. The company has orphan drug designation for antolimab in these conditions, which are characterized by severe inflammation and have no approved treatments, underscoring a significant unmet medical need.
Allakos (Nasdaq: ALLK) announced that two of its oral abstract presentations will be featured at the upcoming EAACI Annual Congress, scheduled for June 6-8, 2020. The presentations will cover the effects of antolimab (AK002) on eosinophil and mast cell-related diseases. The first presentation discusses how a Siglec-8 antibody reduces inflammation, while the second examines the treatment of severe allergic conjunctivitis, highlighting improvements in ocular signs and comorbid conditions. Slides from the presentations will be available on Allakos' website post-event.
On May 11, 2020, Allakos (Nasdaq: ALLK) announced acceptance of an oral presentation at the ASCRS Virtual Annual Meeting, scheduled for May 16, 2020, at 6:00 pm ET. The presentation will focus on a Phase 1b study of antolimab (AK002) in patients with severe allergic conjunctivitis. This study evaluated the drug's effectiveness against three forms of the condition resistant to topical treatments. Following the presentation, slides will be made available on Allakos' website.
Summary not available.